Loading…
Nuvation Bio Inc. is projected to rise to $9.22 by 2027, a +59% move from its current price of $5.81. NUVB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $5.61 | $5.82 | $6.03 | +0.09% |
| Jul 15 | $5.53 | $5.82 | $6.12 | +0.19% |
| Jul 16 | $5.47 | $5.83 | $6.20 | +0.28% |
| Jul 17 | $5.43 | $5.83 | $6.27 | +0.38% |
| Jul 18 | $5.39 | $5.84 | $6.33 | +0.47% |
| Jul 19 | $5.35 | $5.84 | $6.38 | +0.56% |
| Jul 20 | $5.32 | $5.85 | $6.43 | +0.66% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.32 | $5.85 | $6.43 | +0.66% |
| Week 2 | $5.15 | $5.89 | $6.73 | +1.32% |
| Week 3 | $5.03 | $5.93 | $6.99 | +1.99% |
| Week 4 | $4.93 | $5.96 | $7.21 | +2.66% |
| Week 5 | $4.85 | $6.00 | $7.43 | +3.33% |
| Week 6 | $4.79 | $6.04 | $7.63 | +4.01% |
| Week 7 | $4.73 | $6.08 | $7.82 | +4.69% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma. The company was founded in 2018 and is headquartered in New York, New York.
Nuvation Bio operates in the healthcare sector with a focus on oncology therapies, pursuing multiple product candidates to address cancer treatment needs. The description highlights two clinical programs and their intended indications, reflecting the company’s disease areas and trial stages.
NUVB currently trades at $6.11 per share with a market cap of $2.13B and ranks 2006. The near-term technical picture is bullish, with a 30-day range of $4.84 to $7.72, RSI14 at 60, and key moving averages at $5.03 (SMA50) and $5.48 (SMA200). Near-term support sits at $4.58 and resistance at $6.46.
Looking ahead, the long-run forecast envisions a rising price path, with the average price climbing from the current framework toward higher levels through 2050. The projections show a broad expansion in expected values over time, with max values increasing alongside the average prices. This implies a constructive longer-term price trajectory for NUVB, albeit with the inherent uncertainty of forward-looking forecasts.
A major floor 35.7% below — a decisive break under it would weaken the trend.
The nearest floor, 21.2% below — buyers have tended to step in here.
The nearest ceiling, 11.2% above — a clean break opens room to run.
A major ceiling 29.0% above — clearing it would confirm fresh momentum.
Key NUVB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NUVB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.81 | Sell | $5.84 | Sell |
| MA 10 | $5.71 | Buy | $5.76 | Buy |
| MA 20 | $5.60 | Buy | $5.58 | Buy |
| MA 50 | $5.06 | Buy | $5.27 | Buy |
| MA 100 | $4.93 | Buy | $5.19 | Buy |
| MA 200 | $5.50 | Buy | $4.96 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.35 | Neutral |
| Stoch RSI (14) | 16.26 | Buy |
| CCI (20) | 47.10 | Neutral |
| Williams %R (14) | -62.50 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -3.81 | Sell |
| Bollinger %B (20,2) | 0.63 | Neutral |
| Stochastic %K (14) | 37.50 | Neutral |
| TRIX (15) | 0.69 | Buy |
| Awesome (5,34) | 0.54 | Buy |
| Ultimate (7,14,28) | 54.88 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 5.98 | Sell |
| ADX (14) | 16.82 | Neutral |
| ATR (14) | 0.20 | Info |
The near-term technical picture is bullish, supported by a neutral-to-bullish RSI of 60. The stock trades above the SMA50 of $5.03 and near the SMA200 of $5.48, indicating potential upside as price movements reflect positive momentum.
Trading range expectations for the next 30 days show a low of $4.84 and a high of $7.72, suggesting room for price fluctuation within a broad band. A support level of $4.58 and a resistance level of $6.46 provide reference points for potential bounce or breakout scenarios. The stock’s annualized volatility is 70%, underscoring meaningful price swings even within a bullish backdrop.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.05 | $5.81 | $9.36 | 0% | Neutral | |
| $7.12 | $9.22 | $12.74 | +59% | Bullish | |
| $8.13 | $10.92 | $15.82 | +88% | Bullish | |
| $8.52 | $11.83 | $17.76 | +104% | Bullish | |
| $9.12 | $13.02 | $20.15 | +124% | Bullish | |
| $9.78 | $14.33 | $22.76 | +147% | Bullish | |
| $10.16 | $15.26 | $24.82 | +163% | Bullish | |
| $12.62 | $19.40 | $32.22 | +234% | Bullish | |
| $15.23 | $23.92 | $40.50 | +312% | Bullish | |
| $16.74 | $26.86 | $46.31 | +362% | Bullish | |
| $20.89 | $36.98 | $68.69 | +537% | Bullish | |
| $41.23 | $87.10 | $180.00 | +14.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.05 | $5.81 | $6.96 | +0.00% |
| August 2026 | $5.12 | $6.09 | $7.48 | +4.83% |
| September 2026 | $5.27 | $6.33 | $7.89 | +3.89% |
| October 2026 | $5.24 | $6.34 | $8.00 | +0.24% |
| November 2026 | $5.47 | $6.68 | $8.51 | +5.25% |
| December 2026 | $5.93 | $7.28 | $9.36 | +9.05% |
Click any year to see its month-by-month NUVB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, NUVB could reach as high as $9.36, with a base case around $5.81 and support toward $4.05 — roughly 0% from $5.81. Price action looks broadly range-bound.
Expect NUVB to range from $7.12 to $12.74 through 2027. The $9.22 average target implies a +59% move from current prices. That is up +59% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The NUVB price prediction for 2028 points to an average of $10.92 (low $8.13, high $15.82) — a potential gain of +88% on today's $5.81. Momentum favours further upside here.
In 2029, NUVB is projected to trade between $8.52 and $17.76, averaging $11.83 — a potential gain of +104% from today's $5.81. That is up +8% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Nuvation Bio Inc.'s 2030 outlook centres on $13.02, within a $9.12 to $20.15 range. That is up +10% on the projected 2029 average. That marks a +124% change versus current levels. Momentum favours further upside here.
By 2031, NUVB could reach as high as $22.76, with a base case around $14.33 and support toward $9.78 — roughly +147% from $5.81. Buyers look set to stay in control over this stretch.
Expect NUVB to range from $10.16 to $24.82 through 2032. The $15.26 average target implies a +163% move from current prices. That is up +7% on the projected 2031 average. Momentum favours further upside here.
The NUVB price prediction for 2033 points to an average of $19.40 (low $12.62, high $32.22) — a potential gain of +234% on today's $5.81. Buyers look set to stay in control over this stretch.
In 2034, NUVB is projected to trade between $15.23 and $40.50, averaging $23.92 — a potential gain of +312% from today's $5.81. That is up +23% on the projected 2033 average. Momentum favours further upside here.
Nuvation Bio Inc.'s 2035 outlook centres on $26.86, within a $16.74 to $46.31 range. That is up +12% on the projected 2034 average. That marks a +362% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, NUVB could reach as high as $68.69, with a base case around $36.98 and support toward $20.89 — roughly +537% from $5.81. Momentum favours further upside here.
Expect NUVB to range from $41.23 to $180.00 through 2050. The $87.10 average target implies a +14.0x move from current prices. That is up +136% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NUVB today (≈ 172.11704 NUVB) could be worth
$14,991.58
+$13,991.58 (+1399%) by 2050 · US Dollar
Based on the average projected NUVB price of $87.1 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NUVBwould be worth at today's price.
$1,000 invested in NUVB on Jul 10, 2025 (≈ 432.900444 NUVB) would be worth
$2,515.15
+$1,515.15 (+151.5%) today · 2.52× · US Dollar
Based on a NUVB entry price of $2.31 vs. today's $5.81.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.7 | $1,019.3 | +1.9% |
| 1 month ago | $4.58 | $1,268.56 | +26.9% |
| 3 months ago | $4.6 | $1,263.04 | +26.3% |
| 6 months ago | $6.46 | $899.38 | -10.1% |
| 1 year ago | $2.31 | $2,515.15 | +151.5% |
| All time (5.0y) ago | $8.6 | $675.58 | -32.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NUVB forecast.
Our base-case forecast reaches $12.00 around 2030.
Implied market cap at $12.00: $4.17B
The multi-year forecast presents a steadily bullish trajectory with year-by-year targets. The 2026 forecast shows min $4.05, avg $6.11, max $9.93 with neutral sentiment and 0% ROI. By 2027 the avg is $9.79 (min $7.58, max $13.51) and ROI rises to 60.3% with bullish sentiment, followed by 2028 avg $11.73 (min $8.74, max $16.94) and 2029 avg $12.84 (min $9.27, max $19.22) with ROI 92% and 110.1% respectively.
In 2030 the forecast shows avg $14.20 (min $9.98, max $21.91) and ROI 132.5% (bullish); 2031 avg $15.84 (min $10.85, max $25.08) ROI 159.3%; 2032 avg $17.07 (min $11.41, max $27.65) ROI 179.3%; 2033 avg $21.83 (min $14.28, max $36.12) ROI 257.4%; 2034 avg $27.06 (min $17.31, max $45.62) ROI 342.8%; 2035 avg $30.34 (min $19.01, max $52.07) ROI 396.5%.
The ascent continues to 2040 with avg $43.15 (min $24.56, max $79.72) ROI 606.2% and bullish sentiment, and culminates in 2050 with avg $102.25 (min $48.96, max $210.01) ROI 1573.4% within a bullish framework. These figures illustrate a long-run, high-growth scenario, but they are estimates and not guarantees, with significant uncertainty and volatility implied by the higher-end projections.
Tap a question to reveal the answer.
In 2030 the forecast shows min $9.98, avg $14.20, max $21.91 with ROI 132.5% and bullish sentiment.
The long-horizon projections show rising average prices and bullish sentiment from 2027 onward, with a 2030 average of $14.20 and a 2050 average of $102.25. However, 2026 is neutral and there is no guarantee future results will meet these targets.
The forecast’s 2040 max is $79.72 and 2050 max is $210.01, suggesting that a $50 level could be reached along the path, with longer-dated estimates indicating substantial upside potential.
The long-term outlook shows a trajectory toward higher averages, with 2050 avg $102.25 and 2050 max $210.01, supported by bullish sentiment in most years and substantial potential ROI (up to 1573.4%). The 2040 figure also highlights strong upside (avg $43.15, max $79.72).
Current price is $6.11 and the market cap is $2.13B; the asset ranks 2006.
Nuvation Bio Inc. Community Discussion
0Share your Nuvation Bio Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.